Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of COVID-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.
The complement system is a vital part of the immune system. It recognizes and destroys pathogens and protects the body’s own cells with a special component, factor H. Insufficient amounts of factor H lead to excessive inflammation and risk of tissue damage. Emerging evidence suggests that the lung tissue decay observed in severe cases of COVID-19 could be caused by this unregulated inflammation. Current means to inhibit this process use artificial antibodies that block the pathway altogether, stopping the inactivation of pathogens and causing a significant risk of infection. Conversely, supplemented factor H allows for regulated defence while protecting the host cells.
Andreas Schaaf, CEO of Eleva, says: “Unlocking novel therapies is our mission. This path deserves to be explored and may lead to effective treatment of COVID-19.”
Eleva has previously developed recombinant factor H for glomerulopathy and taken it through pre-clinical stages. Studies have indicated a significant reduction in inflammation and tissue damage when factor H was supplemented. Eleva is now looking to accelerate the COVID-19-specific evaluation with a pharmaceutical partner.
